Physician profile
Stanley F Nelson
NPI 1992134688
$118,141.16
in general payments reported to CMS, 2019-2025
7 companies · $5,945 in 2025
The $5,945 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,640 · 2020: $24K · 2021: $17K · 2022: $32K · 2023: $35K · 2024: $2,053 · 2025: $5,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,500 · Honoraria: $2,932 · Food and Beverage: $303 · Travel and Lodging: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,400.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,500.00 |
| Honoraria | $2,931.50 |
| Food and Beverage | $303.14 |
| Travel and Lodging | $288.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $61,537.89 | 2019-2024 | |
| Pfizer INC. | $19,838.67 | 2022-2023 | |
| Sarepta Therapeutics, INC. | $19,659.25 | 2019-2025 | |
| Ns Pharma, INC. | $13,805.00 | 2021-2025 | Viltepso |
| Daiichi Sankyo INC. | $2,250.00 | 2020 | |
| Illumina, INC. | $1,050.00 | 2022 | |
| Travere Therapeutics, INC. | $0.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.